151 related articles for article (PubMed ID: 17918921)
41. Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.
Burch JD; Belley M; Fortin R; Deschênes D; Girard M; Colucci J; Farand J; Therien AG; Mathieu MC; Denis D; Vigneault E; Lévesque JF; Gagné S; Wrona M; Xu D; Clark P; Rowland S; Han Y
Bioorg Med Chem Lett; 2008 Mar; 18(6):2048-54. PubMed ID: 18291643
[TBL] [Abstract][Full Text] [Related]
42. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
43. A novel selective GABA(A) alpha1 receptor agonist displaying sedative and anxiolytic-like properties in rodents.
Selleri S; Bruni F; Costagli C; Costanzo A; Guerrini G; Ciciani G; Gratteri P; Besnard F; Costa B; Montali M; Martini C; Fohlin J; De Siena G; Aiello PM
J Med Chem; 2005 Oct; 48(21):6756-60. PubMed ID: 16220991
[TBL] [Abstract][Full Text] [Related]
44. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
45. Histamine H3 receptor antagonists: from target identification to drug leads.
Bonaventure P; Letavic M; Dugovic C; Wilson S; Aluisio L; Pudiak C; Lord B; Mazur C; Kamme F; Nishino S; Carruthers N; Lovenberg T
Biochem Pharmacol; 2007 Apr; 73(8):1084-96. PubMed ID: 17129577
[TBL] [Abstract][Full Text] [Related]
46. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
47. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.
Hudkins RL; Josef KA; Becknell NC; Aimone LD; Lyons JA; Mathiasen JR; Gruner JA; Raddatz R
Bioorg Med Chem Lett; 2014 Mar; 24(5):1303-6. PubMed ID: 24513042
[TBL] [Abstract][Full Text] [Related]
48. Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.
Dvorak CA; Apodaca R; Xiao W; Jablonowski JA; Bonaventure P; Dugovic C; Shelton J; Lord B; Miller K; Dvorak LK; Lovenberg TW; Carruthers NI
Eur J Med Chem; 2009 Oct; 44(10):4098-106. PubMed ID: 19524331
[TBL] [Abstract][Full Text] [Related]
49. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
50. Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.
Esbenshade TA; Yao BB; Witte DG; Carr TL; Sharma R; Baranowski JL; Krueger KM; Miller TR; Surber BW; Faghih R; Hancock AA
Inflamm Res; 2005 Apr; 54 Suppl 1():S46-7. PubMed ID: 15928830
[No Abstract] [Full Text] [Related]
51. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and stability in biological media of 1H-imidazole-1-carboxylates of ROS203, an antagonist of the histamine H3 receptor.
Rivara M; Vacondio F; Silva C; Zuliani V; Fantini M; Bordi F; Plazzi PV; Bertoni S; Ballabeni V; Flammini L; Barocelli E; Mor M
Chem Biodivers; 2008 Jan; 5(1):140-52. PubMed ID: 18205116
[TBL] [Abstract][Full Text] [Related]
53. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
[TBL] [Abstract][Full Text] [Related]
54. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Bamaung NY; Palazzo F; Zhang Q; Kovar P; Osterling DJ; Hu X; Wilsbacher JL; Johnson EF; Bouska J; Wang J; Bell RL; Davidsen SK; Sheppard GS
Bioorg Med Chem Lett; 2007 Oct; 17(19):5406-9. PubMed ID: 17689078
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.
Jitsuoka M; Tsukahara D; Ito S; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2008 Sep; 18(18):5101-6. PubMed ID: 18768318
[TBL] [Abstract][Full Text] [Related]
56. Autoregulation of McA-RH7777 hepatoma cell proliferation by histamine H3 receptors.
Davenas E; Rouleau A; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2008 Aug; 326(2):406-13. PubMed ID: 18474684
[TBL] [Abstract][Full Text] [Related]
57. New 1-benzyl-4-hydroxypiperidine derivatives as non-imidazole histamine H3 receptor antagonists.
Maslowska-Lipowicz I; Figlus M; Zuiderveld OP; Walczynski K
Arch Pharm (Weinheim); 2008 Dec; 341(12):762-73. PubMed ID: 19009544
[TBL] [Abstract][Full Text] [Related]
58. Pyrazolo [4,3-c] quinolines synthesis and specific inhibition of benzodiazepine receptor binding (Note I).
Savini L; Massarelli P; Pellerano C; Fiorini I; Bruni G; Romeo MR
Farmaco; 1993 Jan; 48(1):65-76. PubMed ID: 8384455
[TBL] [Abstract][Full Text] [Related]
59. Amine-constrained pyridazinone histamine H₃ receptor antagonists.
Sundar BG; Bailey T; Bacon E; Aimone L; Huang Z; Lyons J; Raddatz R; Hudkins R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5543-6. PubMed ID: 21824776
[TBL] [Abstract][Full Text] [Related]
60. Piperidine variations in search for non-imidazole histamine H(3) receptor ligands.
Łazewska D; Kuder K; Ligneau X; Schwartz JC; Schunack W; Stark H; Kieć-Kononowicz K
Bioorg Med Chem; 2008 Sep; 16(18):8729-36. PubMed ID: 18774720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
